Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
The New York Times14h
New York Times - Top Stories
Pete Hegseth Is Sworn In as Defense Secretary After Being Confirmed by Slim Margin Mr. Hegseth has vowed to bring his “warrior” ethos to the Pentagon. His confirmation came down to Vice ...